Abstract
Age-related macular degeneration is among the leading causes of blindness in the USA, and the prevalence is increasing. Although anti-vascular endothelial growth factor (VEGF) therapy has dramatically improved the treatment outcome for patients with wet age-related macular degeneration (AMD), repeated intravitreal injections can be a challenge for patients and physicians. The following provides a review of several innovative approaches to wet AMD therapy currently under investigation. Novel anti-VEGF delivery routes, platelet-derived growth factor (PDGF) receptor antagonism, immunomodulatory therapy, and new imaging technology are all poised to possibly expand the current clinical options available for wet AMD patients. There are a number of exciting new treatment modalities for wet AMD currently being researched. As clinical trials of these new therapies continue, we can hope that improved visual outcomes and patient satisfaction are on the horizon.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
